Navigation Links
FDA-approved drug may slow beta cell destruction in type 1 diabetes patients
Date:12/4/2009

DALLAS Dec. 4, 2009 New findings by UT Southwestern researchers suggest that a drug already used to treat autoimmune disorders might also help slow the destruction of insulin-producing cells in patients recently diagnosed with insulin-dependent (type 1) diabetes.

In type 1 diabetes, formerly known as juvenile diabetes, cells in the pancreas called beta cells, which produce insulin, are destroyed by an autoimmune process.

Researchers at UT Southwestern and 14 other centers worldwide found that injections of the drug rituximab slowed beta cell destruction in the pancreas of those newly diagnosed with type 1 diabetes for at least a year, suggesting a potential treatment option that might improve management and reduce long-term complications of the disease.

Dr. Philip Raskin, professor of internal medicine at UT Southwestern and an author of the study appearing online and in the most recent New England Journal of Medicine, called the findings "extremely exciting."

"Our findings in no way suggest that rituximab should be used as a treatment or that it will eliminate the need for daily insulin injections," said Dr. Raskin, principal investigator of the trial's local effort. "This is not a cure for type 1 diabetes.

"The results do, however, provide evidence that B cells play a significant role in type 1 diabetes and that selective suppression of these B cells may deter the destruction of the body's beta cells."

Prior research has shown that two types of immune cells B cells and T cells help trigger type 1 diabetes. T cells attack and destroy the insulin-producing beta cells. The B cells, however, don't directly attack insulin-producing cells, but researchers have speculated that they trigger the T cells to attack. Rituximab directly attacks and destroys the beta cells.

For the current study, researchers conducted a randomized, double-blind study in which 81 participants received infusions of either rituximab or a placebo once a week for four weeks. The participants, who ranged in age from 8 to 40 years and had been diagnosed with type 1 diabetes within 100 days of enrollment in the study, returned approximately every three months for two years to undergo blood tests and meet with a physician. Two-thirds of the 81 participants received the drug.

The scientists found that after one year, the participants who received rituximab needed lower doses of insulin and were able to produce more of their own insulin than those who received the placebo. They also had better control of their blood sugar.

Dr. Raskin said researchers do not think rituximab could ever be used to completely reverse type 1 diabetes because the pancreas typically is too damaged by the time diabetes is diagnosed.

He also said that while the exact mechanism of how rituximab affects type 1 diabetes remains unclear, the study clearly shows that a therapy that targets B cells may improve beta-cell function in early type 1 diabetes.

The next step, Dr. Raskin said, is to evaluate the potential effects of rituximab in diabetes.


'/>"/>

Contact: Kristen Holland Shear
kristen.hollandshear@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert  

Related medicine news :

1. Video: New FDA-Approved Sun Protectant Saves Skin All Year Round
2. Anesiva Announces Hiring of Sales Force for FDA-Approved Product Zingo(TM)
3. IPM Reaches Landmark Agreement with Pfizer to Develop FDA-Approved Antiretroviral Drug as Vaginal Microbicide
4. Oregon Cosmetic Vein Center Opens in Portland, Among First on West Coast to Offer Brand New, FDA-Approved Procedures and Technologies
5. Edge Health Solutions Releases edgeDMS(TM) 2.0 and edgeMD 2.0(TM), Revolutionary All-in-One Practice Management Software with FDA-Approved Advanced Visualization
6. Newly Published Menopause Study: Bioidentical and FDA-Approved Divigel(R) (estradiol gel) 0.1 Percent Safe and Effective Treatment for Moderate to Severe Hot Flashes Associated With Menopause
7. Grow Back Eyelashes - Orange County Plastic Surgeon Now Helps Patients Grow Longer, Fuller Darker Eyelashes With FDA-Approved Prescription Lash Treatment, Latisse
8. Coapt Systems, Inc. Launches Hydrelle(TM) a New, FDA-Approved Dermal Filler with Lidocaine for Significant Wrinkle Correction and Greater Patient Comfort
9. MultiVu Video Feed: SCIELE PHARMA ANNOUNCES AVAILABILITY OF ULESFIA(TM), FIRST AND ONLY FDA-APPROVED NON-NEUROTOXIC HEAD LICE TREATMENT
10. Introducing anuleaf AD, a New FDA-Approved Hemorrhoid Treatment
11. Upsher-Smith Launches New Website for Divigel(R), a Bioidentical and FDA-Approved Hormone Therapy for Moderate to Severe Hot Flashes, Including Night Sweats, Associated with Menopause
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA-approved drug may slow beta cell destruction in type 1 diabetes patients
(Date:12/7/2016)... ... ... AlignLife clinics nationwide are giving back to their communities by collecting toys ... gifts wrapped tightly under a Christmas Tree. AlignLife hopes to spread the joy ... In exchange for generous donations, customers will receive a gift in return. Anyone ...
(Date:12/7/2016)... Honolulu, HI (PRWEB) , ... December 07, 2016 ... ... Dermatology is proud to announce that its fully redesigned website, which launched October ... well as a sleek responsive design and easy-to-navigate layout. Visitors and patients can ...
(Date:12/7/2016)... ... 07, 2016 , ... 1105 Media’s Live From program has ... Awards competition. Live From won in the Use of Social Media category. The ... projects undertaken by the media industry’s most innovative marketing professionals. , ...
(Date:12/7/2016)... , ... December 07, 2016 ... ... announced its newest portable bioelectronic medicine device WellnessPro Plus for consumers and ... substantially enhances the WellnessPro platform by expanding the treatment modalities available in ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Walking With God: Inspirational ... that will inspire the reader to be aware of God's direction in their lives. ... author, Sanford Smith, retired teacher and active church leader. , Sanford says, ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... , Dec. 7, 2016   TraceLink ... Network for connecting the Life Sciences supply chain ... marketplace, today announced that Tjoapack has selected TraceLink,s ... manufacturing customers comply with the rapidly approaching serialization ... Act (DSCSA) in 2017 and the EU Falsified ...
(Date:12/7/2016)... 7, 2016 According to a new market research ... Product Type (Integrated, Standalone), Model (Knowledge-Based), Type (Therapeutic, Diagnostic), User Interactivity (Active, ... is expected to reach USD 1,519.2 Million by 2021 from USD 856.3 ... Continue Reading ... ...
(Date:12/7/2016)... NEW YORK , December 7, 2016 ... Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ), Anthera Pharmaceuticals ... DNAI ), and AveXis Inc. (NASDAQ: ... Biotechnology Sector Index fell roughly 37% to reach a level ... While it is down by approximately 14% for the year, ...
Breaking Medicine Technology: